Kinnevik AB (publ)

CIK 1766574 · View on SEC EDGAR ↗

Portfolio value
$65.6M
#8,608 of 9,443 by 13F value · top 91.2%
Positions
1
As of
Sept. 30, 2025 Data as of Q3 2025

Portfolio value QoQ: -3.6% 13F does not disclose cash

Top 10 holdings weight
100.00%
Top 25 holdings weight
100.00%
Positions above 1%
1
Effective number of positions
1.0

Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)

Turnover Q3 2025: 0.0% Est. buys $0 · sells $0

Median holding: 4.0 quarters Tracked Q4 2024–Q3 2025 · 100.0% still held

New positions
0
Increased
0
Decreased
0
Closed
0
On this page

Performance vs S&P 500

Tracked Q4 2024–Q3 2025
-27.8%
S&P 500 total return (same window)
+13.4%
Excess return
-41.2%

Annualized: -35.3% · S&P 500: +18.3%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 100.0% · Options excluded: 0.0%

Sector breakdown

Healthcare
100.0%

Full portfolio 1 positions

Type Streak 8Q trend
RXRX Recursion Pharmaceuticals, Inc. - Class A Common Stock $65,558,755 100.00% 13,434,171 $-2,418,151

Top movers (QoQ)

Security Action Shares Δ Value Δ
RXRX Price move only +0 -$2.4M